This document may be deemed to include “forward-looking statements”, including statements, other than statements of historical fact, regarding, among other things the plans for, or progress, scope, cost, duration or results or timing for availability of results of, development of any MAIA drug candidate or program in any indication the potential benefits of any such drug candidate, the period for which MAIA’s funding will be sufficient to fund its operating requirements (runway) or MAIA’s plans, expectations or future operations, financial position, revenues, costs or expenses. MAIA often uses words such as “anticipates”, “believes”, “plans”, “expects”, “projects”, “future”, “intends”, “may”, “will”, “should”, “could”, “estimates”, “predicts”, “potential”, “planned”, “continue”, and similar expressions to identify forward-looking statements. Actual results, performance or experience may differ materially from those expressed or implied by any forward-looking statement as a result of various risks, uncertainties and other factors. No forward-looking statement has been made or reaffirmed without a reasonable basis or has been disclosed other than in good faith. As a result of risks and uncertainties that MAIA faces, the results or events indicated by any forward-looking statement may not occur. MAIA cautions you not to place undue reliance on any forward-looking statement. In addition, any forward-looking statement in this document represents MAIA’s views only as of the date of this document and should not be relied upon as representing its views as of any subsequent date. MAIA disclaims any obligation to update any forward-looking statement, except as required by applicable law.
How to Contact Us
MAIA Biotechnology, Inc.
444 West Lake Street, Suite 1700
Chicago, IL 60606
Last Updated: June 2020